Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Asep Medical Holdings Inc C.ASEP

Alternate Symbol(s):  SEPSF

ASEP Medical Holdings Inc. is a Canada-based company, which is in the business of acquiring research and development assets, technologies and/or businesses in the area of life sciences and medical diagnostics. The Company’s consolidates three development-stage companies, including Sepset Biosciences Inc., ABT Innovations Inc., and SafeCoat Medical Inc. It provides medical devices with an anti-microbial, antifouling coating through its SafeCoat Medical Inc. The Company provides diagnostic kits for predicting the onset of severe Sepsis and organ failure through its Sepset Biosciences Inc. The Company also offers peptide technology through its ABT Innovations Inc. and covers a range of therapeutic applications, including bacterial biofilm infections, anti-inflammatories, anti-infective immune-modulators and vaccine adjuvants. SafeCoat Medical Inc.'s technology incorporates self-assembling biocompatible polymers combined with conjugated antimicrobial peptides.


CSE:ASEP - Post by User

Post by lscfaon Nov 27, 2024 1:23pm
18 Views
Post# 36333972

q3 rersults

q3 rersultsRevenue

The Company recorded an investment in SepSMART of $2,375,000 on the vend in of certain patents licensed to the associate. The revenue from the license is being recognized over the license term of 8 years that commenced December 5, 2023. For the nine month period ended September 30, 2024, revenue of $222,783 has been recorded (2023: $Nil) and the balance of the unearned revenues of $2,131,077 at September 30, 2024 (December 31, 2023: $2,353,860) is recorded as deferred revenue on the condensed interim consolidated statement of financial statements and will be recognized over the remaining term of the license.
<< Previous
Bullboard Posts